Welcome to LookChem.com Sign In|Join Free
  • or
Butanoic acid, 2-nitro-3-oxo-, ethyl ester, also known as Ethyl Nitroacetoacetate, is an organic compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its ester functional group and nitro group, which contribute to its reactivity and potential applications in the chemical and pharmaceutical industries.

51026-98-3

Post Buying Request

51026-98-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

51026-98-3 Usage

Uses

Used in Pharmaceutical Synthesis:
Butanoic acid, 2-nitro-3-oxo-, ethyl ester is used as an intermediate in the synthesis of N-Hydroxy Eltrombopag (H825795), a derivative compound of Eltrombopag (508000). Eltrombopag is an agonist of the Thrombopoietin (Tpo) receptor and is utilized as a treatment for thrombocytopenia, a condition characterized by a low platelet count in the blood.
In the pharmaceutical industry, Ethyl Nitroacetoacetate plays a crucial role in the development of new drugs and therapies, particularly for conditions like thrombocytopenia. Its unique chemical structure allows it to be a versatile building block in the synthesis of complex molecules with potential therapeutic applications.

Check Digit Verification of cas no

The CAS Registry Mumber 51026-98-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,0,2 and 6 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 51026-98:
(7*5)+(6*1)+(5*0)+(4*2)+(3*6)+(2*9)+(1*8)=93
93 % 10 = 3
So 51026-98-3 is a valid CAS Registry Number.

51026-98-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 2-nitro-3-oxobutanoate

1.2 Other means of identification

Product number -
Other names ethyl 2-nitro-3-oxobutyrate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:51026-98-3 SDS

51026-98-3Upstream product

51026-98-3Relevant academic research and scientific papers

Ti(iv)-catalyzed cascade synthesis of tetrahydrofuro[3,2-d]oxazole from arene-1,4-diones

Li, Gang,Li, Li,Huang, Haihong,Yin, Dali

, p. 4418 - 4421 (2015)

A tetrahydrofuro[3,2-d]oxazole scaffold was synthesized efficiently and stereoselectively. The tandem ionic hydrogenation, ketalization, and intramolecular cyclization of arene-1,4-diones with a combination of TiCl4/Et3SiH give facile access to tetrahydrofuro[3,2-d]oxazole derivatives in good yields at room temperature.

Nitro-acetic acid ethyl ester and intermediate preparation method (by machine translation)

-

Paragraph 0037-0050, (2017/11/16)

The invention discloses a nitro-acetic acid ethyl ester and intermediate preparation method. 2 - nitro-acetyl-acetic acid ethyl ester preparation method, comprises the following steps: the acetyl ethyl acetate and through activating the nitric acid reagent from different pipeline entering the micro-channel reactor, the reaction is carried out; wherein the reaction temperature is 5 - 50 °C. By using micro-channel reactor preparing nitro-acetic acid ethyl ester, not only can greatly shorten the reaction time, to enhance the efficiency of the reaction, but also can reduce the generation of by-products, the security is increased, the production cost is reduced, can be suitable for industrial production. (by machine translation)

Synthesis of α-functional nitro compounds by the nitration of activated carbonyl compounds in a two-phase system

Kislyi, V. P.,Laikhter, A. L.,Ugrak, B. I.,Semenov, V. V.

, p. 70 - 74 (2007/10/02)

2-Nitro-1,3-dicarbonyl and α-nitromonocarbonyl compounds were synthesized in the yields variyng from moderate (30percent) to nearly quantitative by the nitration of β-dicarbonyl compounds in a two-phase system: sulfuric/nitric acid mixture - chloroform at -10 - 10 deg C.The use of phase transfer conditions made it possible to avoid the formation of furoxans as by-products and to simplify the isolation of products.This method is quite common for preparing various α-functional nitro compounds including those containing a CF3-group. - Key words: nitration, α-functional nitro compounds.

Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability

Judd,Dowle,Middlemiss,Scopes,Ross,Jack,Pass,Tranquillini,Hobson,Panchal,Stuart,Paton,Hubbard,Hilditch,Drew,Robertson,Clark,Travers,Hunt,et al.

, p. 3108 - 3120 (2007/10/02)

We have identified GR138950, a potent antagonist of the angiotensin II receptor with high oral bioavailability, as our second drug candidate to GR117289. Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability. The strategy was based on SAR established around the diacid GR117289, and from this, it was proposed that a monoacid, in particular a trifluoromethanesulfonamide, should be better absorbed after oral administration and have enhanced oral bioavailability. This led to the identification of GR138950, a potent antihypertensive agent in the renal hypertensive rat, causing sustained falls in blood pressure after oral administration. Oral bioavailability of GR138950 in rats and dogs is high, confirming that GR138950 is well absorbed after oral administration. Moreover, the low plasma clearance and long plasma half-life suggest that this compound will be suitable for once a day administration. Furthermore, the preliminary data indicate that the high bioavailability of GR138950 seen in rats and dogs translates to man. These results demonstrate clearly that GR138950 has the potential to be a clinically effective antihypertensive agent. Further studies are in progress to evaluate GR138950 in the treatment of hypertension.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 51026-98-3